Mitsubishi Tanabe's Key Products And M&A Rumors Tempered By Management Issues

TOKYO - Mitsubishi Tanabe has industry observers scratching their heads. On one hand, the company has rights in Asia for telaprevir, a high-profile hepatitis C treatment, and its oral multiple sclerosis therapy Gilenya (fingolimod) recently gained approval in the U.S. through ex-Japan licensee Novartis and is on file for approval in Japan. But the company's repeated supply chain irregularities raise concern over management's ability to handle its manufacturing quality control process